Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis

Molecular Systems Biology

Volumn 11, Issue 3, 2015, Pages

  Fallahi Sichani, Mohammad ^a   Moerke, Nathan J ^a   Niepel, Mario ^a   Zhang, Tinghu ^a   Gray, Nathanael S ^a   Sorger, Peter K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adaptive responses; BRAFV600E melanomas; cell to cell variability; RAF and MEK inhibitors; submaximal drug effect

Indexed keywords

2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; B RAF KINASE; DORAMAPIMOD; JANUS KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PICTILISIB; PROTEIN C JUN; SELUMETINIB; TOFACITINIB; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL POPULATION; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; MUTATION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84925846085     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.15252/msb.20145877     Document Type: Article

References (67)

1. Alexaki VI, Javelaud D, Mauviel A, (2008) JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 21: 429-438
2. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, et al, (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607
3. Bendall SC, Simonds EF, Qiu P, Amir el-AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, Pe'er D, Tanner SD, Nolan GP, (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332: 687-696
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, et al, (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599
5. Buchkovich K, Duffy LA, Harlow E, (1989) The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58: 1097-1105
6. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL, (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586
7. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N, (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71
8. Chandarlapaty S, (2012) Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2: 311-319
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, et al, (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516
10. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA, (2013) TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 5: 196ra98
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, et al, (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
12. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, et al, (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149: 307-321
13. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK, (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 9: 708-714
14. Fecher LA, Amaravadi RK, Flaherty KT, (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20: 183-189
15. Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS, (2015) Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics 15: 327-339
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB, (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819
17. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, et al, (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703
18. Flusberg DA, Roux J, Spencer SL, Sorger PK, (2013) Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol Biol Cell 24: 2186-2200
19. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, et al, (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575
20. Gaudet S, Janes KA, Albeck JG, Pace EA, Lauffenburger DA, Sorger PK, (2005) A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol Cell Proteomics 4: 1569-1590
21. Geladi P, Kowalski BR, (1986) Partial least-squares regression: a tutorial. Anal Chim Acta 185: 1-17
22. Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, Bordwell A, Can A, Corwin A, Dinn S, Filkins RJ, Hollman D, Kamath V, Kaanumalle S, Kenny K, Larsen M, Lazare M, Li Q, Lowes C, McCulloch CC, McDonough E, et al, (2013) Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci USA 110: 11982-11987
23. de Groot RP, Sassone-Corsi P, (1992) Activation of Jun/AP-1 by protein kinase A. Oncogene 7: 2281-2286
24. Gujral TS, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G, Sorger P, (2013) Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene 32: 3470-3476
25. Gurzov EN, Bakiri L, Alfaro JM, Wagner EF, Izquierdo M, (2008) Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene 27: 641-652
26. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, Reddy SA, Sabapathy K, (2007) c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 14: 218-229
27. Janes KA, Yaffe MB, (2006) Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol 7: 820-828
28. Janes KA, Reinhardt HC, Yaffe MB, (2008) Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell 135: 343-354
29. Jang S, Atkins MB, (2014) Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 95: 24-31
30. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, et al, (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972
31. Johnson AC, Murphy BA, Matelis CM, Rubinstein Y, Piebenga EC, Akers LM, Neta G, Vinson C, Birrer M, (2000) Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol Med 6: 17-27
32. Keith CT, Borisy AA, Stockwell BR, (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71-78
33. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N, (2012) Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22: 668-682
34. Lito P, Rosen N, Solit DB, (2013) Tumor adaptation and resistance to RAF inhibitors. Nat Med 19: 1401-1409
35. Liu J, Lin A, (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15: 36-42
36. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z, (2007) Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11: 447-460
37. Lopez-Bergami P, Kim H, Dewing A, Goydos J, Aaronson S, Ronai Z, (2010) c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem 285: 903-913
38. Magnuson B, Ekim B, Fingar DC, (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441: 1-21
39. Morris MK, Saez-Rodriguez J, Clarke DC, Sorger PK, Lauffenburger DA, (2011) Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Comput Biol 7: e1001099
40. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS, (2012) Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21: 227-239
41. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS, (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977
42. Nead MA, Baglia LA, Antinore MJ, Ludlow JW, McCance DJ, (1998) Rb binds c-Jun and activates transcription. EMBO J 17: 2342-2352
43. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N, (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508
44. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, et al, (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390
45. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J, (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494
46. Sachs K, Gifford D, Jaakkola T, Sorger P, Lauffenburger DA, (2002) Bayesian network approach to cell signaling pathway modeling. Sci STKE 2002: pe38
47. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP, (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308: 523-529
48. Saez-Rodriguez J, Alexopoulos LG, Zhang M, Morris MK, Lauffenburger DA, Sorger PK, (2011) Comparing signaling networks between normal and transformed Hepatocytes using discrete logical models. Cancer Res 71: 5400-5411
49. Scholzen T, Gerdes J, (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322
50. Sevecka M, Wolf-Yadlin A, MacBeath G, (2011) Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling. Mol Cell Proteomics 10: M110.005363
51. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC, (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99
52. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS, (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3: 724
53. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS, (2014a) A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 4: 69-79
54. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS, (2014b) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4: 80-93
55. Solit DB, Rosen N, (2014) Towards a unified model of RAF inhibitor resistance. Cancer Discov 4: 27-30
56. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, et al, (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714
57. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, et al, (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508: 118-122
58. Tang Y, Xie T, Florian S, Moerke N, Shamu C, Benes C, Mitchison TJ, (2013) Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay. J Biomol Screen 18: 1062-1071
59. Vanden Bush TJ, Bishop GA, (2011) CDK-mediated regulation of cell functions via c-Jun phosphorylation and AP-1 activation. PLoS ONE 6: e19468
60. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, et al, (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695
61. Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, et al, (2013) BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2: e00969
62. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, et al, (2014) MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 4: 61-68
63. Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, Packman K, Rosen N, Boylan JF, Heimbrook D, Niu H, (2011) Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res 71: 5535-5545
64. Wisdom R, Johnson RS, Moore C, (1999) c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 18: 188-197
65. Wold S, (1994) Exponentially weighted moving principal components analysis and projections to latent structures. Chemometr Intell Lab Syst 23: 149-161
66. Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B, (2013) Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci USA 110: 18226-18231
67. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS, (2012) Discovery of potent and selective covalent inhibitors of JNK. Chem Biol 19: 140-154